Spero Therapeutics, Inc.
NASDAQ:SPROBiotechnology
+$0.08 today
- Market cap
- $50.92M
- Beta
- 1.46
- P/E (TTM)
- 8.2
- EPS (TTM)
- $0.27
Volume 0.27M
Average 0.78M
SPRO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Spero Therapeutics, Inc.NASDAQ: SPRO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$7.2M, compared with -$14.56M a year earlier. Trailing-twelve-month EBITDA was $14.89M.
Context
- EBITDA amounted to 14.8% of revenue in FY2025, down 136.3 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of -$74.7M (-945.7%) for the fiscal year ending Dec 2026, a slowdown from the +112.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$7.2M-122.7% QoQ
- Last fiscal yearDec 2025
- $8.83M+112.2% YoY
- LTMMar 2026
- $14.89M+121.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +50.5% | — | — |
| 1 year | +112.2% | -945.7% | -1057.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 8.83M USD
- Year-over-year change
- +112.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.83M | +112.2% |
| FY2024 | 2024-12-31 | (72.48M) | -366.9% |
| FY2023 | 2023-12-31 | 27.15M | +163.2% |
| FY2022 | 2022-12-31 | (42.94M) | +50.7% |
| FY2021 | 2021-12-31 | (87.17M) | — |
EBITDA vs competitors
How SPRO compares with its peers on the latest reported figures
- SPRO's LTM Mar 2026 EBITDA of $14.89M is the highest of the 10 companies compared; the peer median is -$64.35M.
- Its year-over-year change of +121.1% is the highest of 10, against a peer median of +12.2%.
- EBITDA amounts to 27.2% of revenue for SPRO, versus a peer median of 874.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.89M | +121.1% | — | 27.2% | |
| LTM Mar 2026 | -$19.31M | +41.5% | — | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | -$21.52M | +14.5% | — | — |
| LTM Mar 2026 | -$30.19M | -68.1% | — | — | |
| LTM Mar 2026 | -$41.87M | +24.2% | — | 3650.0% | |
| LTM Mar 2026 | -$64.35M | +18.9% | — | 427.9% | |
| LTM Mar 2026 | -$81.94M | +12.2% | — | — | |
| LTM Mar 2026 | -$84.28M | -67.4% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$104.73M | -226.0% | — | 874.0% |
| LTM Mar 2026 | -$108.82M | +2.8% | — | — | |
| Peer median (excluding SPRO) | -$64.35M | +12.2% | — | 874.0% | |
Competitors are the stored peer set for SPRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.07M | 48.58M | 103.78M | 47.98M | 59.62M |
| Cost of Revenue | 0 | 0 | 51.44M | 96.76M | 0 |
| Gross Profit | 3.07M | 48.58M | 52.34M | (48.78M) | 59.62M |
| Gross Margin | 100.0% | 100.0% | 50.4% | -101.7% | 100.0% |
| Research & Development | 64.53M | 47.59M | 51.44M | 96.76M | 38.47M |
| Selling, General & Admin | 41.7M | 36.48M | 25.55M | 23.7M | 21.18M |
| Operating Expenses | 91.04M | 90.78M | 30.86M | 24.58M | 59.64M |
| Depreciation & Amortization | 646K | 869K | 367K | 2K | 0 |
| EBITDA | (87.17M) | (42.94M) | 27.15M | (72.48M) | 8.83M |
| EBITDA Margin | -2839.4% | -88.4% | 26.2% | -151.1% | 14.8% |
| Operating Income | (87.97M) | (42.2M) | 21.48M | (73.36M) | (24K) |
| Operating Margin | -2865.5% | -86.9% | 20.7% | -152.9% | -0.0% |
| Interest Income | 346K | 1.11M | 3.94M | 4.74M | 2.51M |
| Interest Expense | 1.94M | 2.61M | 0 | 0 | 0 |
| Other Income / Expenses | (1.79M) | (4.22M) | 3.92M | 4.8M | 8.86M |
| Income Before Tax | (89.76M) | (46.42M) | 25.4M | (68.57M) | 8.83M |
| Pre-Tax Margin | -2923.6% | -95.5% | 24.5% | -142.9% | 14.8% |
| Income Tax Expense | 0 | 0 | 2.6M | 0 | 261K |
| Net Income | (89.76M) | (46.42M) | 22.81M | (68.57M) | 8.57M |
| Net Margin | -2923.6% | -95.5% | 22.0% | -142.9% | 14.4% |
| EPS (Basic) | (2.91) | (1.23) | 0.43 | (1.27) | 0.15 |
| EPS (Diluted) | (2.91) | (1.23) | 0.43 | (1.27) | 0.15 |
| Weighted Avg Shares | 30.9M | 37.59M | 52.7M | 54.04M | 56.02M |
| Weighted Avg Shares (Diluted) | 30.9M | 37.59M | 52.99M | 54.04M | 59.04M |
Spero Therapeutics, Inc.
NASDAQ:SPRO
Intrinsic Alpha fair value
Locked
Current Price
$0.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.